⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
CVKD News
Cadrenal Therapeutics, Inc. Common Stock
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Announces End-of-Phase 2 Meeting with the FDA and Pivotal Phase 3 Registration Path for CAD-1005 in Heparin-Induced Thrombocytopenia (HIT)
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Reports Fourth Quarter 2025 Financial Results; Provides Corporate Update on CAD-1005 Program for HIT Following End-of-Phase 2 FDA Meeting
globenewswire.com
CVKD
Life Sciences Virtual Investor Forum Presentations Now Available for Online Viewing
globenewswire.com
JUNS
DYAI
PHIO
CVKD
TNXP
MTVA
XAIR
AEMD
NSRX
ICU
JAGX
Form 8-K
sec.gov
CVKD
Cadrenal Therapeutics Highlights Research Supporting 12-LOX Inhibition in Reducing Inflammation in Obesity and Type 2 Diabetes
globenewswire.com
CVKD
Cadrenal Therapeutics Highlights Recent 12-LOX Inhibitor Platform Expansion
globenewswire.com
CVKD
Form 8-K
sec.gov
CVKD